bioRxiv · 10.1101/2020.12.10.420224
Effective host-directed therapy for tuberculosis by targeted depletion of myeloid-derived suppressor cells using a diphtheria toxin-based fusion protein
Abstract
Myeloid-derived suppressor cells (MDSCs) are present in elevated numbers in TB patients and have been found to be permissive for Mycobacterium tuberculosis (Mtb) proliferation. To determine whether depletion of MDSCs may improve host control of TB, we used a novel diphtheria toxin-based fusion protein known as DABIL-4 that targets and depletes IL-4-receptor positive cells. We show that DABIL-4 depletes both PMN-MDSCs and M-MDSC in the mouse TB model, and that it reduces the lung bacillary burden of Mtb. These results indicate that MDSC-depleting therapies targeting the IL4 receptor are beneficial in TB and offer an avenue towards host-directed TB therapy.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Parveen, S., Lun, S., Urbanowski, M. E., Cardin, M., Murphy, J. R., Bishai, W. R.. 2020-12-10. Effective host-directed therapy for tuberculosis by targeted depletion of myeloid-derived suppressor cells using a diphtheria toxin-based fusion protein. https://doi.org/10.1101/2020.12.10.420224
Cite the original work for its findings. Save a collection to share your selection of sources.